Prosecution Insights
Last updated: November 12, 2026

Nrl Pharma Inc.

Technology area: Biotechnology & Pharmaceuticals

1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready

Analysis

Nrl Pharma Inc. currently has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This single action is assigned to 1 distinct examiner, HA, JULIE, within 1 distinct art unit. HA, JULIE is the busiest examiner for the company, with 1 busiest examiner pending action. This 1 to 1 ratio across actions, examiners, and art units indicates a very focused prosecution point. The 1 pending office action represents the full extent of the company's active engagement with the patent office in this sector.

Because there is only 1 distinct examiner and 1 distinct art unit, the prosecution strategy is entirely dependent on the interactions with HA, JULIE. The busiest examiner pending count of 1 confirms that no other examiners are currently reviewing work for Nrl Pharma Inc. This concentration simplifies the management of the portfolio, as there are no competing examiner perspectives to reconcile. Practitioners should prioritize understanding the specific preferences of HA, JULIE within the context of the 1 art unit involved. The 1 pending office action serves as the sole focus of the company's current patent efforts.

Written from this page's own data; every figure is computed from USPTO records and verified before publication.

Portfolio Summary

1
Total Pending OAs
1
Non-Final OAs
0
Final Rejections
0
Advisory / Quayle

Case Difficulty Mix

Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.

1
Hard (100%)
0
Medium (0%)
0
Easy (0%)
0
Unknown (0%)

Rejection Statute Mix

BucketCases
Multi-statute (no §101)1 (100%)

Industry Mix

How the docket's pending cases split across USPTO tech-center bands.

1
Life Sciences
100% of docket
0
Information Tech
0% of docket
0
Communications
0% of docket
0
Semiconductors
0% of docket
0
Mechanical / Eng
0% of docket
0
Business / Other
0% of docket

Time-on-OA Estimate

Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.

10 h
Manual time on pending OAs
2 h
Time saved (low, 20%)
4 h
Time saved (mid, 35%)
0.1 wks
FTE-weeks freed (mid)

Top Examiners on this docket

ExaminerApps on this docketAllow rateInterview lift
HA, JULIE 1 75.8% +44.0%

Hard Cases (1)

Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.

App #TitleExaminerDue in
18896681 AGENT AND COMPOSITION FOR IMPROVING INTRAUTERINE BACTERIAL FLORA, AND METHOD FOR DETERMINING WHETHER INTRAUTERINE BACTERIAL FLORA HAS BEEN IMPROVED OR NORMALIZED HA, JULIE —

Interview Candidates (1)

Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.

App #TitleExaminerDue in
18896681 AGENT AND COMPOSITION FOR IMPROVING INTRAUTERINE BACTERIAL FLORA, AND METHOD FOR DETERMINING WHETHER INTRAUTERINE BACTERIAL FLORA HAS BEEN IMPROVED OR NORMALIZED HA, JULIE —

Top Art Units

Art UnitApps
1654 1

Pending Office Actions

App #TitleExaminerArt UnitStatutesStatusDue inAIFiled
18896681 AGENT AND COMPOSITION FOR IMPROVING INTRAUTERINE BACTERIAL FLORA, AND METHOD FOR DETERMINING WHETHER INTRAUTERINE BACTERIAL FLORA HAS BEEN IMPROVED OR NORMALIZED HA, JULIE 1654 §102§103 Non-Final OA — Pending Sep 25, 2024

Managing Nrl Pharma Inc.'s Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Frequently Asked Questions

How many pending USPTO office actions does Nrl Pharma Inc. have?

Nrl Pharma Inc. has 1 pending office actions as of November 2026, spread across 1 art units and 1 examiners.

Which USPTO examiner handles the most Nrl Pharma Inc. applications?

Julie Ha has the most, with 1 of Nrl Pharma Inc.'s pending office actions.

What technology area are Nrl Pharma Inc.'s patent applications in?

Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month